Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Teulings HE, Tjin EPM, Willemsen KJ, van der Kleij S, Ter Meulen S, Kemp EH, Krebbers G, van Noesel CJM, Franken CLMC, Drijfhout JW, Melief CJM, Nieuweboer-Krobotova L, Nieweg OE, van der Hage JA, van der Veen JPW, Relyveld GN, Luiten RM.

Oncoimmunology. 2018 Jan 15;7(4):e1419113. doi: 10.1080/2162402X.2017.1419113. eCollection 2018.

2.

Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre.

Teulings HE, Lommerts JE, Wolkerstorfer A, Nieuweboer-Krobotova L, Luiten RM, Bekkenk MW, van der Veen JP.

Br J Dermatol. 2017 Feb;176(2):503-506. doi: 10.1111/bjd.14790. Epub 2016 Nov 11. No abstract available.

PMID:
27273338
3.

Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.

Teulings HE, Tjin EP, Willemsen KJ, Krebbers G, van Noesel CJ, Kemp EH, Nieuweboer-Krobotova L, van der Veen JP, Luiten RM.

Br J Dermatol. 2013 Apr;168(4):733-8. doi: 10.1111/bjd.12136. Epub 2013 Feb 27.

PMID:
23421690
4.

Hyperpigmentation: types, diagnostics and targeted treatment options.

Nieuweboer-Krobotova L.

J Eur Acad Dermatol Venereol. 2013 Jan;27 Suppl 1:2-4. doi: 10.1111/jdv.12048. Review.

PMID:
23205538
5.

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners.

Teulings HE, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, Wolkerstorfer AW, Luiten RM, van der Veen JP.

Br J Dermatol. 2013 Jan;168(1):162-71. doi: 10.1111/bjd.12111.

PMID:
23136900
6.

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.

Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europe´enne des Me´decins Spe´cialistes (UEMS).

Br J Dermatol. 2013 Jan;168(1):5-19. doi: 10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2.

PMID:
22860621
7.

A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients.

Linthorst Homan MW, Spuls PI, Nieuweboer-Krobotova L, de Korte J, Sprangers MA, Bos JD, Wolkerstorfer A, van der Veen JP.

J Eur Acad Dermatol Venereol. 2012 Jun;26(6):690-5. doi: 10.1111/j.1468-3083.2011.04147.x. Epub 2011 Jun 29.

PMID:
21711467
8.

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study.

Meesters AA, Wind BS, Kroon MW, Wolkerstorfer A, van der Veen JP, Nieuweboer-Krobotová L, van der Wal AC, Bos JD, Beek JF.

J Am Acad Dermatol. 2011 Dec;65(6):1173-9. doi: 10.1016/j.jaad.2010.07.049.

PMID:
21641077
9.

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo.

Elassiuty YE, Klarquist J, Speiser J, Yousef RM, El Refaee AA, Hunter NS, Shaker OG, Gundeti M, Nieuweboer-Krobotova L, Le Poole IC.

Exp Dermatol. 2011 Jun;20(6):496-501. doi: 10.1111/j.1600-0625.2010.01232.x. Epub 2011 Mar 22.

10.

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.

Kroon MW, Wind BS, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A.

J Am Acad Dermatol. 2011 Mar;64(3):516-23. doi: 10.1016/j.jaad.2010.01.048. Epub 2011 Jan 20.

PMID:
21255869
11.

Punchgraft testing in vitiligo; effects of UVA, NB-UVB and 632.8 nm Helium-Neon laser on the outcome.

Wind BS, Meesters AA, Kroon MW, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A.

J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1236-7. doi: 10.1111/j.1468-3083.2010.03874.x. Epub 2010 Oct 6. No abstract available.

PMID:
21039919
12.

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study.

Wind BS, Kroon MW, Meesters AA, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A.

Lasers Surg Med. 2010 Sep;42(7):607-12. doi: 10.1002/lsm.20937.

PMID:
20806385
13.

Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire study.

Wind BS, Kroon MW, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Meesters AA, Bos JD, Wolkerstorfer A.

Br J Dermatol. 2010 May;162(5):1142-4. doi: 10.1111/j.1365-2133.2010.09678.x. Epub 2010 Mar 1. No abstract available.

PMID:
20199553
14.

Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity.

Fongers A, Wolkerstorfer A, Nieuweboer-Krobotova L, Krawczyk P, Tóth GG, van der Veen JP.

Br J Dermatol. 2009 Nov;161(5):1105-11. doi: 10.1111/j.1365-2133.2009.09367.x. Epub 2009 Jun 22.

PMID:
19673878
15.

Linkage and association of HLA class II genes with vitiligo in a Dutch population.

Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ.

Br J Dermatol. 2001 Jul;145(1):90-4.

PMID:
11453913
16.
17.
18.

Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.

Westerhof W, Nieuweboer-Krobotova L.

Arch Dermatol. 1997 Dec;133(12):1525-8.

PMID:
9420536

Supplemental Content

Loading ...
Support Center